Assaf P. Moore

Radiation Oncology

1275 York Ave
New York, NY 10065

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 57 publications

Two-year toxicity and PSA dynamics in the initial cohort of the SABR-Dual trial - two-fraction stereotactic radiotherapy for localized prostate cancer using rectal spacing.

Two-year toxicity and PSA dynamics in the initial cohort of the SABR-Dual trial - two-fraction stereotactic radiotherapy for localized prostate cancer using rectal spacing.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: February 04, 2026

Postoperative Epidural Disease and Local Control After Separation Surgery and Spine Stereotactic Body Radiation Therapy.

Postoperative Epidural Disease and Local Control After Separation Surgery and Spine Stereotactic Body Radiation Therapy.

Journal: International journal of radiation oncology, biology, physics

Published: January 27, 2026

Early outcomes of partial gland (focal) salvage brachytherapy for radiorecurrent prostate cancer.

Early outcomes of partial gland (focal) salvage brachytherapy for radiorecurrent prostate cancer.

Journal: Brachytherapy

Published: November 24, 2025

BRAF inhibitor or BRAF/MEK inhibitor treatment for patients with metastatic BRAF V600E mutated differentiated thyroid cancer.

BRAF inhibitor or BRAF/MEK inhibitor treatment for patients with metastatic BRAF V600E mutated differentiated thyroid cancer.

Journal: Archives of endocrinology and metabolism

Published: October 31, 2025

Stereotactic Radiotherapy to the Prostate and Pelvic Lymph Nodes for High-Risk and Very High-Risk Prostate Cancer in a Setting with a Hydrogel Spacer: A Toxicity Report.

Stereotactic Radiotherapy to the Prostate and Pelvic Lymph Nodes for High-Risk and Very High-Risk Prostate Cancer in a Setting with a Hydrogel Spacer: A Toxicity Report.

Journal: Cancers

Published: May 15, 2025

Acute Toxicity and Early Prostate Specific Antigen Response After Two-Fraction Stereotactic Radiation Therapy for Localized Prostate Cancer Using Peri-Rectal Spacing-Initial Report of the SABR-Dual Trial.

Acute Toxicity and Early Prostate Specific Antigen Response After Two-Fraction Stereotactic Radiation Therapy for Localized Prostate Cancer Using Peri-Rectal Spacing-Initial Report of the SABR-Dual Trial.

Journal: International journal of radiation oncology, biology, physics

Published: April 18, 2024

The role of a radiopaque peri-rectal hydrogel spacer in aiding accurate daily image-guidance for prostate stereotactic radiotherapy.

The role of a radiopaque peri-rectal hydrogel spacer in aiding accurate daily image-guidance for prostate stereotactic radiotherapy.

Journal: Frontiers in oncology

Published: February 14, 2024

Effect of Radiological Tumor Thickness on Prognosis of Early Glottic-Squamous Cell Carcinoma Treated With Radiation.

Effect of Radiological Tumor Thickness on Prognosis of Early Glottic-Squamous Cell Carcinoma Treated With Radiation.

Journal: Journal of voice : official journal of the Voice Foundation

Published: December 20, 2023

Assessing the effect of metastasis-directed therapy in oligometastatic disease using the restricted mean survival time.

Assessing the effect of metastasis-directed therapy in oligometastatic disease using the restricted mean survival time.

Journal: British journal of cancer

Published: December 06, 2023

40 Gray in 5 Fractions for Salvage Reirradiation of Spine Lesions Previously Treated With Stereotactic Body Radiotherapy.

40 Gray in 5 Fractions for Salvage Reirradiation of Spine Lesions Previously Treated With Stereotactic Body Radiotherapy.

Journal: Neurosurgery

Published: October 05, 2023

Long-term Outcomes from a Phase 1 Dose Escalation Study Using Stereotactic Body Radiotherapy for Patients with Low- or Intermediate-risk Prostate Cancer.

Long-term Outcomes from a Phase 1 Dose Escalation Study Using Stereotactic Body Radiotherapy for Patients with Low- or Intermediate-risk Prostate Cancer.

Journal: European urology oncology

Published: August 30, 2023

SABR-Dual: a phase II/III trial of two-fraction versus five-fraction stereotactic radiotherapy for localized low- and favorable intermediate-risk prostate cancer.

SABR-Dual: a phase II/III trial of two-fraction versus five-fraction stereotactic radiotherapy for localized low- and favorable intermediate-risk prostate cancer.

Journal: BMC cancer

Published: July 06, 2023

Showing 1-12 of 57

Last Updated: 09/26/2026